Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

Inclusion Criteria

• •All patients must meet the following criteria to be eligible for study entry:
• •Pathologically confirmed invasive ductal carcinoma or invasive lobular carcinoma of the breast, T2-T3 / T4a-c / N0-2 / M0, with positive estrogen and/or progesterone receptors, and Her-2-neu negative. Patients with inflammatory breast cancer will not be included (T4d). Patients previously treated patients with no measurable disease or patients with metastatic disease will be excluded.
• •Give written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
• •Patients must be postmenopausal, defined as one of the following:
• •* Patients \> 50 years of age with no spontaneous menses for at least 12 months,
• •* Bilateral oophorectomy
• •Be ambulatory (outpatient) and have an ECOG PS \<1.
• •Patients must have measurable disease by mammogram and/or breast ultrasound (in special cases a dedicated breast MRI may be clinically indicated). The target lesion must not have been previously irradiated.
• •No prior chemotherapy.
• •Patients must have adequate organ and marrow function as defined as follows: absolute neutrophil count \> 1,500/mm3, hemoglobin \> 8.0 g/dl, platelets \> 75,000/mm3, total bilirubin \< 2 mg/dl, serum creatinine \< 2 mg/dl, Transaminases (AST, ALT) may be up to 2 x institutional upper limit of normal. In addition \< 1 gr of protein in 24 hr urine collection and urine protein/creatinine ratio \< 1.0.
• •No life threatening parenchymal disease or rapidly progressing disease warranting cytotoxic chemotherapy.
• •Hypertension must be controlled (\<150/100 mmHg).
• •Ejection Fraction \> 50% by echocardiogram. (LVEF greater than 75% at baseline should be reviewed and/or the test repeated as it may be falsely elevated).
• •No history of thrombosis during the previous 12 months.